Antisense Therapeutics To Undertake Clinical Trial of ALT1102 in Duchenne Muscular Dystrophy at the Melbourne Royal Children’s Hospital

Antisense Therapeutics (ANP) has announced that the company has undertaken advanced planning for the clinical trial of ALT1102, its immunomodulatory therapy initially in development for the treatment of Multiple Sclerosis (MS). The trial is designed to assess the drug’s effects on the inflammation associated with this rare and incurable muscle wasting disease of children (Duchenne Muscular Dystrophy).

KEY TAKEAWAYS:

• Company to undertake a clinical trial of its drug ATL1102 in new clinical application, Duchenne Muscular Dystrophy
• Clinical trial is planned to be undertaken at the Royal Children’s Hospital (RCH), Melbourne
• World class international advisory board established chaired by Mr William Goolsbee ANP’s non-executive director and ex-Chairman of Sarepta Therapeutics
• Funding secured for the trial (subject to receipt of approval to commence the trial)
• Australian Ethical Investment to become largest shareholder in the Company

Mark Diamond, CEO of Antisense Therapeutics said: “Our plan to undertake a clinical trial of ATL1102 in DMD patients is facilitated by the extensive pre-clinical and clinical experience that we have established via ATL1102’s development in MS. As DMD is a rare disease with a high unmet medical need, ATL1102 is expected to benefit materially from development incentives, including orphan drug designation that are provided to support rare disease drug development”.

More Information

Request Information